Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Genomic profiles and treatment outcomes in young adults with stage IV non-small cell lung cancer (NSCLC): Insights from the Middle East.

Kholoud Alqasem, Sakhr Alshwayyat, Salsabeel Aljawabrah et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20690

e20690 Background: NSCLCs in young adults account for less than 10% of all NSCLCs and show distinct mutational profiles compared to those in elderly patie...

Vitamin D deficiency in prostate cancer: Prevalence in a sun-rich climate and the influence of androgen deprivation therapy.

Nazmul Hasan, Dalia Kaakour, Omid Yazdanpanah et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17096

e17096 Background: Vitamin D is essential for calcium absorption, bone health, and immune function. Despite the abundant sunlight in Southern California,...

TUB-030, a novel ADC targeting 5T4: A phase I/IIa multi-center, first-in-human clinical trial (5-STAR 1-01) in patients with advanced solid tumors.

Shiraj Sen, Sheena Sahota, Lillian L. Siu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps3164

TPS3164 Background: TUB-030 is a novel antibody-drug conjugate (ADC) targeting 5T4, an oncofetal antigen expressed in vari...

Analysis of the results of intravesical perfusion therapy combined with immediate or non-immediate hematoporphyrin intravesical perfusion photodynamic therapy (PDT) after TURBT for NMIBC.

Linjun Hu, Chengming Xie, Xingli Shan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16593

e16593 Background: NMIBC has a high postoperative recurrence rate. Therefore, Hematoporphyrin intravesical perfusion PDT being explored to reduce the recu...

Malignant giant cell tumor of bone: A case series in the denosumab era.

Emanuela Palmerini, Rodrigo Vasquez, Alberto Righi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23510

e23510 Background: Giant cell tumor of bone (GCTB) is a locally recurrent, rarely metastasizing tumor. However, GCTB can undergo malignant transformation....

Real world adverse events of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy.

Hassaan Ahmad, Noor Ahmad Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19552

e19552 Background: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy was approved by the FDA in Feb...

Astrocytoma survival patterns and key prognostic factors: A population-based study.

Belal Mohamed Hamed, Muzamil Khan, Jehad Feras AlSamhori et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14026

e14026 Background: Astrocytoma is a glioma that arises from astrocytes in the central nervous system and is classified into four grades (I-IV) based on ma...

Immune related kidney toxicity, management, and outcomes in ICI treated patients with advanced or metastatic cancers.

Zara Izadi, Youbei Lou, Ying Zhang et al. Jun 01, 2025 pp. 2601-2601 10.1200/jco.2025.43.16_suppl.2601

2601 Background: The impact of kidney immune-related adverse events (KirAEs) and their management (mgmt) on clinical outcomes in patients receiving immune...

Outcomes of metastatic esophageal and gastroesophageal junction cancers: A 13-year single-center study.

Hadil Zureigat, Muaz Alsabbagh Alchirazi, Ahmed Nabil Mohamed Hassan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16061

e16061 Background: The prognosis of metastatic esophageal (Eso) and gastroesophageal (GEJ) cancers is poor. However, the introduction of immunotherapy and...

A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial.

Rachel Occhiogrosso Abelman, Shannon McLaughlin, Geoffrey G. Fell et al. Jun 01, 2025 pp. 511-511 10.1200/jco.2025.43.16_suppl.511

511 Background: Sacituzumab govitecan (SG) is a TROP-2 directed antibody-drug conjugate (ADC) approved for metastatic trip...

Efficacy of immune checkpoint inhibitors versus chemotherapy in metastatic urothelial carcinoma: A systematic review and meta-analysis.

Rahul Navab, Nehemias Antonio Guevara Rodriguez, Aasta Kumari et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16560

e16560 Background: Metastatic urothelial carcinoma (mUC) is conventionally managed with platinum-based chemotherapy, which might be effective but is often...

Genomic newborn screening for cancer risk: A retrospective cohort study.

Lisa Diller, Andy Bhattacharjee, Abigail Cinelli et al. Jun 01, 2025 pp. 10014-10014 10.1200/jco.2025.43.16_suppl.10014

10014 Background: Population-based newborn screening (NBS) improves outcomes through early detection of rare pediatric conditions. Cancer is a leading cau...

Outcomes of Ph-like B-lineage acute lymphoblastic leukemia in the era of novel therapies.

Hamed Rahmani Youshanlouei, Syed Abdul Mannan Shah, Francisca Anazco et al. Jun 01, 2025 pp. 6535-6535 10.1200/jco.2025.43.16_suppl.6535

6535 Background: Ph-likeALL) is a high-risk subset of B-ALL with poor treatment response and high relapse rates. We examined outcomes of Ph-like B-ALL pts...

Efficacy and safety of atezolizumab and bevacizumab with or without transarterial chemoembolization as first-line therapy for advanced hepatocellular carcinoma: An international multicenter real-world study.

Ningning Zhang, Kaipeng Liu, Yuexi Yu et al. Jun 01, 2025 pp. 4105-4105 10.1200/jco.2025.43.16_suppl.4105

4105 Background: Transarterial chemoembolization (TACE) combined with immunotherapy and targeted therapy provides a promising therapy for advanced hepatoc...

Evaluation of novel MUC1-c targeted near-infrared imaging agent for fluorescence-guided surgery of cancer.

Qi Mao, Mengjie Zhang, Rui Xu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15072

e15072 Background: Tumor-targeted, near-infrared (NIR) fluorescent is an emerging field of real-time intraoperative imaging. Targeted NIR dyes contain NIR...

The individual and joint effects of air pollution exposure on plasma proteome among vulnerable elderly: Implications for lung cancer risk in the Cancer Prevention Study-II Nutrition Cohort.

Ziyin Tang, Ying Wang, Jeremy A. Sarnat et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22576

e22576 Background: The biological mechanisms underlying air pollution-induced lung carcinogenesis remained underexplored. We assessed individual and joint...

Effect of fusion of radiomic, pathomic, and clinical biomarkers on multi-scale tumor biology and OS stratification in HNSCC receiving standard of care (SOC).

Omid Haji Maghsoudi, Haojia Li, Lauren Brady et al. Jun 01, 2025 pp. 6046-6046 10.1200/jco.2025.43.16_suppl.6046

6046 Background: SOC immunotherapy (IO) for head and neck squamous cell carcinoma (HNSCC) has limited efficacy with inadeq...

Well-being Pathway (We-Path): An Italian integrative oncology community-based program for cancer survivors.

Giorgia Razzini, Laura Bernaroli, Maria Grazia Lazzaretti et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13874

e13874 Background: Integrative oncology underlines the role of nutrition, physical activity, and healthy lifestyle habits in enhancing survival and mitiga...

Health-related quality of life (HRQoL) outcomes with darolutamide in the phase 3 ARANOTE trial.

Alicia K. Morgans, Kunhi Parambath Haresh, Mindaugas Jievaltas et al. Jun 01, 2025 pp. 5004-5004 10.1200/jco.2025.43.16_suppl.5004

5004 Background: Effective and well tolerated treatments to maintain HRQoL are essential for patients with metastatic hormone-sensitive prostate cancer (m...

Incidence of malignant and premalignant conditions in LGBTQIA+ individuals on gender-affirming hormone therapy: A systematic review and meta-analysis.

Ujjwal Soni, Nidhi Lanka, Muhammad Abdullah Humayun et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22580

e22580 Background: LGBTQIA+ individuals comprise approximately 7.1% of the U.S. population. Gender-affirming hormone therapy (GAHT) is integral to transit...

Trends in gastric cancer mortality in the US: A population-based analysis, 1999-2023.

Maha Zafar, Abdul Qadeer, Sardar Muhammad Imran Khan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16072

e16072 Background: Gastric cancer is a leading cause of mortality worldwide, with pronounced variations in outcomes across populations. This study investi...

HLA allele, TCR V- and J-gene segment usage combinations and their association with survival in neuroblastoma.

Eddie Fung, George Blanck, Taha Huda et al. Jun 01, 2025 pp. 10042-10042 10.1200/jco.2025.43.16_suppl.10042

10042 Background: Neuroblastoma has variable outcomes across different risk groups. In children with stage 4 neuroblastoma, five-year overall remains arou...

A phase 1/2 study of vusolimogene oderparepvec (RP1) in primary melanoma (mel) to reduce the risk of sentinel lymph node (SLN) metastasis.

Urvashi Mitbander Joshi, Jabra Zarka, Hong Wang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps9607

TPS9607 Background: The majority of 100,000 annual new U.S. cases of mel consist of localized early-stage disease that undergo wide local excision (WLE) +...

Plasma metabolomic signatures for predicting pancreatic ductal adenocarcinoma survival: The clinical application of targeted mass spectrometry lipidomics.

Paulo D'Amora, Ismael DCG Silva, Adam Jeremiah Nagourney et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16409

e16409 Background: Pancreatic ductal adenocarcinoma (PDAC) is one the most lethal human cancers with an overall 5-year survival of 12%. Diagnostic and pro...

Effect of co-occurring TP53 and intracellular proliferation pathway mutations on disease recurrence and survival benefits in head and neck cancers.

Rajnish Vasant Nagarkar, Mohsina Hussain, Sirshendu Roy et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18046

e18046 Background: Head and neck cancer (HNC) is often driven by genetic alterations, particularly co-occurring mutations in TP53 gene and key proliferati...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page